Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post $16.78 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Amicus Therapeutics’ earnings, with the lowest sales estimate coming in at $16.31 million and the highest estimate coming in at $17.30 million. Amicus Therapeutics reported sales of $4.17 million in the same quarter last year, which indicates a positive year-over-year growth rate of 302.4%. The business is scheduled to issue its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Amicus Therapeutics will report full year sales of $16.78 million for the current year, with estimates ranging from $80.96 million to $85.74 million. For the next year, analysts forecast that the company will report sales of $161.81 million per share, with estimates ranging from $116.74 million to $200.44 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.11). The business had revenue of $14.73 million for the quarter, compared to analysts’ expectations of $14.50 million. Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%.
Shares of Amicus Therapeutics (FOLD) traded up $0.01 during trading hours on Friday, reaching $15.17. 7,937,537 shares of the company’s stock were exchanged, compared to its average volume of 3,710,000. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53. The stock has a market capitalization of $2,520.00, a price-to-earnings ratio of -18.06 and a beta of 1.59. Amicus Therapeutics has a one year low of $6.41 and a one year high of $17.40.
In related news, insider Jay Barth sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $15.05, for a total transaction of $75,250.00. Following the sale, the insider now directly owns 90,409 shares in the company, valued at $1,360,655.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc bought 335,827 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The shares were purchased at an average price of $13.56 per share, for a total transaction of $4,553,814.12. The disclosure for this purchase can be found here. Insiders have sold 207,870 shares of company stock worth $3,066,112 over the last 90 days. Insiders own 3.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB purchased a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $219,000. Delek Group Ltd. purchased a new position in Amicus Therapeutics in the fourth quarter valued at approximately $1,581,000. MetLife Investment Advisors LLC purchased a new position in Amicus Therapeutics in the fourth quarter valued at approximately $1,108,000. Crestline Management LP increased its stake in Amicus Therapeutics by 133.2% in the fourth quarter. Crestline Management LP now owns 123,222 shares of the biopharmaceutical company’s stock valued at $1,773,000 after purchasing an additional 70,377 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Amicus Therapeutics in the fourth quarter valued at approximately $18,974,000.
WARNING: “Amicus Therapeutics, Inc. (FOLD) Expected to Post Quarterly Sales of $16.78 Million” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://stocknewstimes.com/2018/03/14/amicus-therapeutics-inc-fold-expected-to-post-quarterly-sales-of-16-78-million.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.